At present, no consensus has been already reached regarding the assessment of patients who need to be investigated with both 18F-FDG and 68Ga-DOTA-peptide PET/CT (even if it is more probable that NET neoplasms with Ki67 > 15% will have positive lesions in 18F-FDG PET/CT [64, 65]). This evidence concerns the gene MKI67 and neoplasm.